No description available.

No description available.

No description available.

Recent research, that has been focused on recognition memory, has revealed that two processes contribute to recognition of previously encountered items: recollection and familiarity (Aggleton & Brown, 1999; Eichenbaum, 2006; Eichenbaum, Yonelinas, & Ranganath, 2007; Rugg & Yonelinas, 2003; Skinner & Fernandes, 2007; Squire, Stark, & Clark, 2004; Wixted, 2007a; Yonelinas, 2001a; Yonelinas, 2002). The findings of neural correlates of recollection and familiarity lead to the assumption that there are different brain regions activated in either process, but there are, to the best of my knowledge, no studies assessing how these brain regions are working together in a recollection or a familiarity network, respectively. Additionally, there are almost no studies to date, which directly searched for overlapping regions. Therefore, in study I of the current thesis, brain regions associated to both recognition processes are searched investigated. Additionally, a connectivity analysis will search for functional correlated brain activations that either build a recollection or a familiarity network. It is undoubtable that the Brain Derived Neurotrophic Factor (BDNF) is strongly involved in synaptic plasticity in the hippocampus (Bramham & Messaoudi, 2005) and there is evidence that a genetic variant of this neurotrophin (BDNF 66Met) is related to poorer memory performance (Egan, et al., 2003). Therefore, in study II of the current thesis, the effect of BDNF Val66Met on recollection and familiarity performance and related brain activations is investigated. Finally, one could summarize, that serotonin, like BDNF, is strongly involved in brain development and plasticity as well as in learning and memory processes (Vizi, 2008). More precisely, there is evidence for alterations in the structure of brain regions, which are known to be involved in emotional memory formation and retrieval, like amygdala and hippocampus (Frodl, et al., 2008; Munafo, Brown, & Hariri, 2008; Pezawas, et al., 2005). One study found an slight epistatic effect of BDNF and 5-HTTLPR on the grey matter volume of the amygdala (Pezawas, et al., 2008). Therefore, in study III, it is investigated if such an interaction effect could be substantiated for the amygdala and additionally revealed for the hippocampus. The results of the current thesis allow further comprehension of recollection, hence episodic memory, and point to a special role of the BDNF in temporal and prefrontal brain regions. Additionally, the finding of an epistatic effect between BDNF and serotonin transporter function point to the need of analyzing interactions between genes and also between genes and environmental factors which reveals more information than the study of main effects alone. In conclusion, analyzing behavioral and neural correlates of episodic memory reveal allowed insights in brain functions that may serve as guideline for future studies in clinical populations with memory deficits, including susceptibility factors such as good or bad environment, as well as promising gene variants that influence episodic memory.

Recent research, that has been focused on recognition memory, has revealed that two processes contribute to recognition of previously encountered items: recollection and familiarity (Aggleton & Brown, 1999; Eichenbaum, 2006; Eichenbaum, Yonelinas, & Ranganath, 2007; Rugg & Yonelinas, 2003; Skinner & Fernandes, 2007; Squire, Stark, & Clark, 2004; Wixted, 2007a; Yonelinas, 2001a; Yonelinas, 2002). The findings of neural correlates of recollection and familiarity lead to the assumption that there are different brain regions activated in either process, but there are, to the best of my knowledge, no studies assessing how these brain regions are working together in a recollection or a familiarity network, respectively. Additionally, there are almost no studies to date, which directly searched for overlapping regions. Therefore, in study I of the current thesis, brain regions associated to both recognition processes are searched investigated. Additionally, a connectivity analysis will search for functional correlated brain activations that either build a recollection or a familiarity network. It is undoubtable that the Brain Derived Neurotrophic Factor (BDNF) is strongly involved in synaptic plasticity in the hippocampus (Bramham & Messaoudi, 2005) and there is evidence that a genetic variant of this neurotrophin (BDNF 66Met) is related to poorer memory performance (Egan, et al., 2003). Therefore, in study II of the current thesis, the effect of BDNF Val66Met on recollection and familiarity performance and related brain activations is investigated. Finally, one could summarize, that serotonin, like BDNF, is strongly involved in brain development and plasticity as well as in learning and memory processes (Vizi, 2008). More precisely, there is evidence for alterations in the structure of brain regions, which are known to be involved in emotional memory formation and retrieval, like amygdala and hippocampus (Frodl, et al., 2008; Munafo, Brown, & Hariri, 2008; Pezawas, et al., 2005). One study found an slight epistatic effect of BDNF and 5-HTTLPR on the grey matter volume of the amygdala (Pezawas, et al., 2008). Therefore, in study III, it is investigated if such an interaction effect could be substantiated for the amygdala and additionally revealed for the hippocampus. The results of the current thesis allow further comprehension of recollection, hence episodic memory, and point to a special role of the BDNF in temporal and prefrontal brain regions. Additionally, the finding of an epistatic effect between BDNF and serotonin transporter function point to the need of analyzing interactions between genes and also between genes and environmental factors which reveals more information than the study of main effects alone. In conclusion, analyzing behavioral and neural correlates of episodic memory reveal allowed insights in brain functions that may serve as guideline for future studies in clinical populations with memory deficits, including susceptibility factors such as good or bad environment, as well as promising gene variants that influence episodic memory.

No description available.

No description available.

No description available.

Die Wirkung von zwei endogen neuroprotektiven Substanzen, Melatonin und 17 beta-Estradiol wurde an drei Caspase-abhängigen, apoptotischen, aber Exzitotoxin-unabhängigen Schadensmodellen an neuronalen Primärkulturen untersucht und mit der bei vorwiegend nekrotischen Schadensmodellen verglichen. Es zeigten sich eine Abhängigkeit des neuroprotektiven Potentials von der Art des Zelluntergangs sowie unterschiedliche Mechanismen der Neuroprotektion. Melatonin wirkte in allen drei apoptischen Modellen nicht neuroprotektiv, sondern verstärkte die Schädigung der Neurone noch, während partiell gegen die OGD-induzierte Nekrose (OGD, engl. Oxygen glucose deprivation, kombinierter Sauerstoff- und Glukoseentzug) kortikaler Neurone Schutz erzielt wurde. Der Einsatz des endogenen neuroprotektiven Faktors Melatonin als Therapeutikum ist möglicherweise nur bei neurodegenerativen Erkrankungen mit exzitotoxischer Schädigung durch Glutamat oder oxidativem Stress wie bei Epilepsie oder dem Schlaganfall durch Ischämie sinnvoll. Die fehlende bzw. potenzierenden Wirkung von Melatonin bei neuronaler Apoptose in vitro, stellt jedoch einen therapeutischen Erfolg bei der Behandlung der mit apoptotischer Schädigung einhergehenden Alzheimer'schen Erkrankung in Frage. Bei klinischer Anwendung ist auch der von uns erhobene Befund zu beachten, dass in vitro native neuronale Zellen durch Melatonin geschädigt werden. 17 beta-Estradiol wirkte sowohl bei nekrotischer als auch bei apoptotischer Zellschädigung. Dabei zeigten sich wesentliche Unterschiede in den Mechanismen der Neuroprotektion und in der Ansprechbarkeit verschiedener Regionen des Gehirns. Schutz vor Apoptose konnte nur durch eine Langzeitvorbehandlung (20 h) in septalen und hippokampalen Kulturen, nicht jedoch in kortikalen Kulturen beobachtet werden. Dieser Effekt liess sich durch Rezeptorantagonisten, Proteinsynthesehemmung sowie durch Hemmung der Phosphoinositol-3-Kinase blockieren. Eine Kurzzeitbehandlung war gegen Apoptose nicht wirksam, zeigte gegen OGD und Glutamattoxizität jedoch neuroprotektives Potential. Dieser Effekt liess sich nicht antagonisieren, so dass hier ein direkter antioxidativer Mechanismus wahrscheinlich erscheint. Die antiapoptotische Wirkung in septalen und hippokampalen Kulturen korrelierte mit einer höheren Dichte des Estrogenrezeptors-alpha und einer erhöhten Expression antiapoptotischer Proteine in diesen Regionen. Da bei der Alzheimer'schen Erkrankung der Kortex betroffen ist, könnte der fehlende Effekt von 17 beta-Estradiol in kortikalen Neuronen sowohl auf die neuronale Apoptose als auch auf die Proteinexpression von Bcl-2 und Bcl-xL möglicherweise auf experimenteller Basis erklären, warum eine langfristige Estrogentherapie bei Frauen mit milder bis moderater Alzeimer'scher Erkrankung den Progress der Erkrankung nicht aufhalten konnte (Mulnard et al. 2000). / The neuroprotective effect of melatonin and 17 beta-estradiol has been evaluated in several in vitro models of neuronal apoptosis and necrosis. Melatonin was not neuroprotective in three models of apoptosis but showed a pro-apoptotic effect in primary cortical neurons. Melatonin revealed to damage naïve neurons, too. Partial protection was observed against necrotic neurodegeneration after oxygen-glucose deprivation (OGD). The use of melatonin as a therapeutic agent might be of interest in neurodegenerative diseases with excitotoxic damage like epilepsia or ischemia, but is questioned in case of apoptotic neurodegeneration. 17 beta-estradiol was neuroprotectiv in both necrotic and apoptotic neurodegeneration. Differences in the mechanism of neuroprotetion and in the efficacy in different regions of the brain were observed. A neuroprotective effect was visible only in hippocampal and septal cultures if 17 beta-estradiol was applied 20 h prior (long term pre-treatment) but not in cortical neurons. This effect correlates with an increased density of estrogen receptor-alpha and an increased expression of anti-apoptotic proteins like Bcl-2 and Bcl-xL in these regions. These effect could be blocked with receptor antagonists, protein synthesis inhibitors and an inhibitor of the phosphatidylinositol 3-kinase. A short term pre-treatment revealed a receptor independent neuroprotective potential against OGD and glutamate toxicity. The failure of 17 beta-estradiol to protect cortical neurons against apoptosis could be an experimental basis to understand, why a long lasting treatment with estrogens of women with mild to moderate Alzheimer´s disease failed to inhibit the progress of the illness (Mulnard et al., 2000)